Clarification sought from Glenmark Pharmaceuticals

30 Oct 2015 Evaluate

The Exchange has sought clarification from Glenmark Pharmaceuticals with reference to news reported on CNBC TV18 on October 29, 2015 -‘Setback For Glenmark: Sanofi received license Vatelizumab in 2011 & Sanofi not to Pursue Development Of Vatelizumab Molecule.’

The above information is a part of company’s filings submitted to BSE.

Glenmark Pharma Share Price

1919.05 -46.70 (-2.38%)
08-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1795.30
Dr. Reddys Lab 1267.15
Cipla 1497.45
Zydus Lifesciences 924.35
Lupin 2071.35
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×